company background image
BLAB

Britannia Life Sciences CNSX:BLAB Stock Report

Last Price

CA$0.14

Market Cap

CA$23.5m

7D

0%

1Y

n/a

Updated

15 Aug, 2022

Data

Company Financials
BLAB fundamental analysis
Snowflake Score
Valuation3/6
Future Growth0/6
Past Performance0/6
Financial Health2/6
Dividends0/6

BLAB Stock Overview

Britannia Life Sciences Inc. provides product testing, safety assessment, and compliance services to the cosmetics, nutraceutical, and consumer packaged goods industries in the United Kingdom and internationally.

Britannia Life Sciences Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Britannia Life Sciences
Historical stock prices
Current Share PriceCA$0.14
52 Week HighCA$0.32
52 Week LowCA$0.085
Beta0
1 Month Change38.10%
3 Month Change7.41%
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO-46.30%

Recent News & Updates

Shareholder Returns

BLABCA Professional ServicesCA Market
7D0%1.2%3.0%
1Yn/a4.1%0.7%

Return vs Industry: Insufficient data to determine how BLAB performed against the Canadian Professional Services industry.

Return vs Market: Insufficient data to determine how BLAB performed against the Canadian Market.

Price Volatility

Is BLAB's price volatile compared to industry and market?
BLAB volatility
BLAB Average Weekly Movement17.4%
Professional Services Industry Average Movement8.7%
Market Average Movement10.6%
10% most volatile stocks in CA Market18.9%
10% least volatile stocks in CA Market4.3%

Stable Share Price: BLAB is more volatile than 75% of Canadian stocks over the past 3 months, typically moving +/- 17% a week.

Volatility Over Time: BLAB's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of Canadian stocks.

About the Company

FoundedEmployeesCEOWebsite
n/a28Pete Shippenhttps://britannia.life

Britannia Life Sciences Inc. provides product testing, safety assessment, and compliance services to the cosmetics, nutraceutical, and consumer packaged goods industries in the United Kingdom and internationally. The company is based in Toronto, Canada.

Britannia Life Sciences Fundamentals Summary

How do Britannia Life Sciences's earnings and revenue compare to its market cap?
BLAB fundamental statistics
Market CapCA$23.52m
Earnings (TTM)-CA$15.46m
Revenue (TTM)CA$7.30m

3.2x

P/S Ratio

-1.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
BLAB income statement (TTM)
RevenueCA$7.30m
Cost of RevenueCA$2.03m
Gross ProfitCA$5.27m
Other ExpensesCA$20.72m
Earnings-CA$15.46m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.095
Gross Margin72.13%
Net Profit Margin-211.76%
Debt/Equity Ratio91.4%

How did BLAB perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is BLAB undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BLAB?

Other financial metrics that can be useful for relative valuation.

BLAB key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue4.3x
Enterprise Value/EBITDA17.8x
PEG Ration/a

Price to Sales Ratio vs Peers

How does BLAB's PS Ratio compare to its peers?

BLAB PS Ratio vs Peers
The above table shows the PS ratio for BLAB vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average4.1x
RIWI RIWI
2.7xn/aCA$13.7m
FARM Deveron
7.5x53.4%CA$70.4m
MYID Reklaim
5.8xn/aCA$7.4m
GSL Green Scientific Labs Holdings
0.5xn/aCA$4.2m
BLAB Britannia Life Sciences
3.2xn/aCA$23.5m

Price-To-Sales vs Peers: BLAB is good value based on its Price-To-Sales Ratio (3.2x) compared to the peer average (4.1x).


Price to Earnings Ratio vs Industry

How does BLAB's PE Ratio compare vs other companies in the North American Professional Services Industry?

Price-To-Sales vs Industry: BLAB is expensive based on its Price-To-Sales Ratio (3.2x) compared to the Canadian Professional Services industry average (2.2x)


Price to Sales Ratio vs Fair Ratio

What is BLAB's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BLAB PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio3.2x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate BLAB's Price-To-Sales Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of BLAB when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: BLAB (CA$0.15) is trading below our estimate of fair value (CA$3.93)

Significantly Below Fair Value: BLAB is trading below fair value by more than 20%.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies

Future Growth

How is Britannia Life Sciences forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


25.1%

Forecasted Commercial Services industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Britannia Life Sciences has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Discover growth companies

  • Examine whether Britannia Life Sciences is trading at an attractive price based on how much it is expected to earn in the future, and relative to its industry peers and the wider market.
  • Britannia Life Sciences competitive advantages and company strategy can generally be found in its financial reports archived here.

Past Performance

How has Britannia Life Sciences performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-9,735.9%

Last years earnings growth

Earnings and Revenue History

Quality Earnings: BLAB is currently unprofitable.

Growing Profit Margin: BLAB is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if BLAB's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare BLAB's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BLAB is unprofitable, making it difficult to compare its past year earnings growth to the Professional Services industry (21.1%).


Return on Equity

High ROE: BLAB has a negative Return on Equity (-255.08%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Britannia Life Sciences's financial position?

Financial Health Score

2/6

Financial Health Score 2/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: BLAB's short term assets (CA$3.5M) do not cover its short term liabilities (CA$8.3M).

Long Term Liabilities: BLAB's short term assets (CA$3.5M) do not cover its long term liabilities (CA$7.3M).


Debt to Equity History and Analysis

Debt Level: BLAB's net debt to equity ratio (61.7%) is considered high.

Reducing Debt: Insufficient data to determine if BLAB's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable BLAB has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: BLAB is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 143.8% per year.


Discover healthy companies

Dividend

What is Britannia Life Sciences's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate BLAB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate BLAB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BLAB's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BLAB's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as BLAB has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

3.6yrs

Average management tenure


CEO

Pete Shippen (41 yo)

3.58yrs

Tenure

Mr. Peter James Shippen, also known as Pete, CPA, CAIA, serves as Director of Myplas USA, Inc. He served as the President at Redwood Asset Management Inc. since September 2009 and served as the firm’s Chie...


Leadership Team

Experienced Management: BLAB's management team is considered experienced (3.6 years average tenure).


Board Members

Experienced Board: BLAB's board of directors are considered experienced (3.6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: BLAB only recently listed within the past 12 months.


Top Shareholders

Company Information

Britannia Life Sciences Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Britannia Life Sciences Inc.
  • Ticker: BLAB
  • Exchange: CNSX
  • Founded: NaN
  • Industry: Research and Consulting Services
  • Sector: Commercial Services
  • Implied Market Cap: CA$23.524m
  • Shares outstanding: 162.23m
  • Website: https://britannia.life

Number of Employees


Location

  • Britannia Life Sciences Inc.
  • 120 Adelaide Street West
  • Suite 2400
  • Toronto
  • Ontario
  • M5H 1T1
  • Canada

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/08/15 00:00
End of Day Share Price2022/08/15 00:00
Earnings2022/03/31
Annual Earnings2022/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.